Molecular Insight Pharmaceuticals, Inc. has developed a series of 123I-labeled and 99mTc-labeled small molecules for targeting the extracellular domain of prostate-specific membrane antigen (PSMA), a target initially selected for the diagnostic assessment of primary and metastatic prostate cancer [12, 13]. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.